CoChat

Recommended Guidelines for Validation, Quality Control, and Reporting of TP53 Variants in Clinical Practice

Open access
Leroy, Bernard, Ballinger, Mandy L., Baran-Marszak, Fanny, Bond, Gareth L., Braithwaite, Antony, Concin, Nicole, Donehower, Lawrence A., El-Deiry, Wafik S., Fenaux, Pierre, Gaidano, Gianluca, Langerød, Anita, Hellstrom-Lindberg, Eva, Iggo, Richard, Lehmann-Che, Jacqueline, Mai, Phuong L., Malkin, David, Moll, Ute M., Myers, Jeffrey N., Nichols, Kim E., Pospisilova, Sarka, Ashton-Prolla, Patricia, Rossi, Davide, Savage, Sharon A., Strong, Louise C., Tonin, Patricia N., Zeillinger, Robert, Zenz, Thorsten, Fraumeni, Joseph F., Taschner, Peter E.M., Hainaut, Pierre, Soussi, Thierry · 2017 · Cancer Research
Cited by 91

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Abstract

Accurate assessment of TP53 gene status in sporadic tumors and in the germline of individuals at high risk of cancer due to Li–Fraumeni Syndrome (LFS) has important clinical implications for diagnosis, surveillance, and therapy. Genomic data from more than 20,000 cancer genomes provide a wealth of information on cancer gene alterations and have confirmed TP53 as the most commonly mutated gene in human cancer. Analysis of a database of 70,000 TP53 variants reveals that the two newly discovered exons of the gene, exons 9β and 9γ, generated by alternative splicing, are the targets of inactivating mutation events in breast, liver, and head and neck tumors. Furthermore, germline rearrange-ments in intron 1 of TP53 are associated with LFS and are frequently observed in sporadic osteosarcoma. In this context of constantly growing genomic data, we discuss how screening strategies must be improved when assessing TP53 status in clinical samples. Finally, we discuss how TP53 alterations should be described by using accurate nomenclature to avoid confusion in scientific and clinical reports. Cancer Res; 77(6); 1250–60. ©2017 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-16-2179

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 24 references

Cited by

See all 91

Metadata

Authors
Leroy, B., Ballinger, M. L., Baran-Marszak, F., Bond, G. L., Braithwaite, A., Concin, N., Donehower, L. A., El-Deiry, W. S., Fenaux, P., Gaidano, G., Langerød, A., Hellstrom-Lindberg, E., Iggo, R., Lehmann-Che, J., Mai, P. L., Malkin, D., Moll, U. M., Myers, J. N., Nichols, K. E., Pospisilova, S., Ashton-Prolla, P., Rossi, D., Savage, S. A., Strong, L. C., Tonin, P. N., Zeillinger, R., Zenz, T., Fraumeni, J. F., Taschner, P. E. M., Hainaut, P., & Soussi, T.
Venue
Cancer Research
Published
2017-03-14
Volume
77
Issue
6
Pages
1250-1260
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W2591837371
Cited by
91
References
24
FWCI
4.09
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Recommended Guidelines for Validation, Quality Control, and Reporting of TP53 Variants in Clinical Practice. https://app.cochat.ai/papers/10.1158/0008-5472.can-16-2179
The paper
Leroy, B., Ballinger, M. L., Baran-Marszak, F., Bond, G. L., Braithwaite, A., Concin, N., Donehower, L. A., El-Deiry, W. S., Fenaux, P., Gaidano, G., Langerød, A., Hellstrom-Lindberg, E., Iggo, R., Lehmann-Che, J., Mai, P. L., Malkin, D., Moll, U. M., Myers, J. N., Nichols, K. E., . . . Soussi, T. (2017). Recommended Guidelines for Validation, Quality Control, and Reporting of TP53 Variants in Clinical Practice. Cancer Research. https://doi.org/10.1158/0008-5472.can-16-2179

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.